Madrigal Pharmaceuticals, Inc. or Ultragenyx Pharmaceutical Inc.: Who Invests More in Innovation?

Biotech Giants' R&D Race: Ultragenyx vs. Madrigal

__timestampMadrigal Pharmaceuticals, Inc.Ultragenyx Pharmaceutical Inc.
Wednesday, January 1, 20146820500045967000
Thursday, January 1, 201554218000114737000
Friday, January 1, 201615934000183204000
Sunday, January 1, 201724390000231644000
Monday, January 1, 201825389000293998000
Tuesday, January 1, 201972324000357355000
Wednesday, January 1, 2020184809000412084000
Friday, January 1, 2021205164000497153000
Saturday, January 1, 2022245441000705789000
Sunday, January 1, 2023271823000648449000
Loading chart...

Data in motion

Investing in Innovation: A Tale of Two Biotech Giants

In the competitive world of biotechnology, innovation is the lifeblood of success. Madrigal Pharmaceuticals, Inc. and Ultragenyx Pharmaceutical Inc. have been at the forefront of this race, investing heavily in research and development (R&D) over the past decade. From 2014 to 2023, Ultragenyx consistently outpaced Madrigal, with R&D expenses peaking at 705% of Madrigal's 2014 investment by 2022. This trend underscores Ultragenyx's commitment to pioneering new treatments and therapies. Meanwhile, Madrigal has shown a steady increase in its R&D spending, growing by approximately 400% over the same period. This strategic investment highlights Madrigal's dedication to innovation, albeit at a more measured pace. As these companies continue to push the boundaries of medical science, their financial commitment to R&D will likely play a pivotal role in shaping the future of healthcare.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025